Compare Amphastar Pharmaceuticals Inc (AMPH) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Prudential PLC — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Prudential PLC trades at $27.46 (market cap $34.98B). The key difference: Prudential PLC is far larger — about 40.5× Amphastar Pharmaceuticals Inc's market cap, and Prudential PLC pays a 1.89% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | PUK | |
|---|---|---|
Market Cap | $863.95M | $34.98B |
Sector | Health | Financials |
52-Week High | $30.81 | $33.61 |
52-Week Low | $16.87 | $24.98 |
Enterprise Value | $1.26B | $36.41B |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Prudential Financial (PUK) trades at $28.28, up 1.43% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with Q2 2025 and Q4 2025 earnings beats, robust 14.52% net income margin, and improving cash flow trends. Recent news highlights China regulatory concerns impacting Asian-focused insurers, though Prudential reported solid Q2 2026 results with $985 million net income.
The stock presents value characteristics with a low P/E of 9.21, supported by analyst consensus leaning bullish (50% buy ratings). Key risks include China regulatory exposure and competitive pressures in Asian markets. Upside potential exists if the company successfully executes its capital-light strategy and navigates geopolitical challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
